Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients
- 1 December 2019
- journal article
- research article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 19 (6) , e741-e747
Abstract
No abstract availableKeywords
Funding Information
- American College of Surgeons
- National Institutes of Health
This publication has 24 references indexed in Scilit:
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast CancerNew England Journal of Medicine, 2019
- Adjuvant Capecitabine for Breast Cancer after Preoperative ChemotherapyNew England Journal of Medicine, 2017
- Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patientsBreast Cancer Research and Treatment, 2017
- Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant ChemotherapyAnnals of Surgical Oncology, 2015
- Breast Cancer, Version 1.2016Journal of the National Comprehensive Cancer Network, 2015
- Pathological Complete Response in Neoadjuvant Treatment of Breast CancerAnnals of Surgical Oncology, 2015
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapyEuropean Journal of Cancer, 2012
- Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast CancerAnnals of Surgical Oncology, 2011
- Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancerHuman Pathology, 2008